Ep. 16: “T Cell Regulation” Featuring Dr. Dario Vignali
Manage episode 305560506 series 2895470
Dr. Dario Vignali is the Frank Dixon Chair in Cancer Immunology and Vice Chair and Professor of Immunology at University of Pittsburgh School of Medicine. His lab studies various aspects of T cell regulation, and recently generated a new mouse model to target conventional CD4 T cells.
Featured Products and Resources:
- Keep current with the latest in immune regulation research.
- Use EasySepTM to isolate highly purified immune cells in as little as 8 minutes.
The Immunology Science Round Up
Dual Targeting for B Cell Leukemia – CAR T therapy targeting both CD19 and CD22 showed clinical activity and low toxicity in a Phase I trial, but strategies to further improve CAR T cell persistence are needed.
Microbial Fitness in the Intestine – Researchers showed that microbial exposure leads to the selection of antigen-specific intestinal plasma cells with a diverse Ig gene repertoire.
Less Is More for COVID-19 Vaccine Dosage – A 1000-fold lower prime dose of an adenovirus-based SARS-CoV-2 vaccine followed by a standard boost dose elicited superior immune responses compared to two standard doses.
IL-33 in Inflammation Resolution – IL-33 induces metabolic reprogramming, which controls the differentiation of alternatively activated macrophages that contribute to the resolution of inflammation and tissue repair.
Image courtesy of Dr. Dario Vignali